(Q77601628)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Candesartan cilexetil. A review of its use in essential hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

main subject

essential hypertension

1 reference

K J McClellan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

K L Goa

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

847-869

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9829158%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-199856050-00013

6 December 2019

exact match

0 references

cites work

Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats

1 reference

12 December 2020

Modulation of the renin-angiotensin-aldosterone system and cough.

1 reference

12 December 2020

Blockade of the renin-angiotensin system

1 reference

12 December 2020

Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil

1 reference

12 December 2020

1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee

1 reference

12 December 2020

Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension

1 reference

12 December 2020

Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis

1 reference

12 December 2020

Angiotensin II receptor subtypes: selective antagonists and functional correlates

1 reference

12 December 2020

Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.

1 reference

12 December 2020

The 1996 report of a World Health Organization expert committee on hypertension control

1 reference

12 December 2020

Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.

1 reference

12 December 2020

Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis.

1 reference

12 December 2020

Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.

1 reference

12 December 2020

Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators.

1 reference

12 December 2020

Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor

1 reference

12 December 2020

Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers

1 reference

12 December 2020

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

12 December 2020

AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats

1 reference

12 December 2020

Role of the renin-angiotensin system in hypertension in the elderly

1 reference

12 December 2020

Candesartan Causes Long-lasting Antagonism of the Angiotensin II Receptor-mediated Contractile Effects in Isolated Vascular Preparations: a Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174)

1 reference

12 December 2020

Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist

1 reference

12 December 2020

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor

1 reference

12 December 2020

Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.

1 reference

12 December 2020

A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension

1 reference

12 December 2020

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

12 December 2020

Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects

1 reference

12 December 2020

Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats

1 reference

12 December 2020

Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats

1 reference

12 December 2020

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators

1 reference

12 December 2020

Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension

1 reference

12 December 2020

Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116

1 reference

12 December 2020

Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes

1 reference

12 December 2020

Human angiotensin receptor subtypes.

1 reference

12 December 2020

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy

1 reference

12 December 2020

The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population

1 reference

12 December 2020

Pharmacokinetic drug interaction studies with candesartan cilexetil

1 reference

12 December 2020

Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects

1 reference

12 December 2020

Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide

1 reference

12 December 2020

Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension

1 reference

12 December 2020

Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).

1 reference

12 December 2020

Angiotensin receptor antagonists as a treatment for hypertension

1 reference

12 December 2020

Molecular biology of angiotensin II biosynthesis and receptors

1 reference

12 December 2020

Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats

1 reference

12 December 2020

Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro

1 reference

12 December 2020

Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers

1 reference

12 December 2020

Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients

1 reference

12 December 2020

Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats.

1 reference

12 December 2020

Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.

1 reference

12 December 2020

Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.

1 reference

12 December 2020

An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat

1 reference

12 December 2020

Antihypertensive effects of candesartan cilexetil, enalapril and placebo

1 reference

12 December 2020

Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators

1 reference

12 December 2020

Proposed update of angiotensin receptor nomenclature.

1 reference

12 December 2020

Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

1 reference

12 December 2020

Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury

1 reference

12 December 2020

TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats

1 reference

12 December 2020